Mizuho Securities analyst Mara Goldstein maintained a Buy rating on TCR2 Therapeutics (TCRR) today and set a price target of $51.00. The company’s shares closed last Tuesday at $17.86.
According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 13.8% and a 38.4% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.
Currently, the analyst consensus on TCR2 Therapeutics is a Strong Buy with an average price target of $46.50, a 156.2% upside from current levels. In a report issued on June 11, BMO Capital also maintained a Buy rating on the stock with a $53.00 price target.
See today’s analyst top recommended stocks >>
TCR2 Therapeutics’ market cap is currently $689.6M and has a P/E ratio of -7.50. The company has a Price to Book ratio of 1.91.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TCRR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TCR2 Therapeutics, Inc. is an immunotherapy company, which develops biological drugs and engineering T-cells for cancer therapy. The company offers cancer therapy, T-cell biology, Immunology and Molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded in May 2015 and is headquartered in Cambridge, MA.
